摘要
目的:研究雷公藤多苷对实验性自身免疫性重症肌无力(experimental autoimmune myasthenia gravis,EAMG)大鼠的治疗作用。方法:建立EAMG动物模型,依据Lennon评分法及体质量监测,初步评定雷公藤多苷对EAMG大鼠的治疗作用;并采用实时荧光定量聚合酶链式反应(real-time polymerase chain reaction,RT-PCR)方法,检测完全弗氏佐剂组、EAMG模型组、雷公藤多苷治疗组大鼠胸腺及外周血单个核细胞T细胞受体(T-cell receptor,TCR)BV基因信使核糖核酸(mRNA)的表达情况。结果:雷公藤多苷可以改善EAMG大鼠肌无力症状,降低Lennon评分,增加大鼠体质量。EAMG模型大鼠TCR BV基因表达谱呈现偏移,而雷公藤多苷治疗组大鼠的mRNA表达量有所下降,差异具有统计学意义(P<0.05)。结论:雷公藤多苷能有效缓解EAMG大鼠的临床症状,能控制EAMG大鼠基因的偏移,可降低特异性活化的抗原反应性T细胞活性。
OBJECTIVE：To explore the therapeutic efficacy of tripterygium glycosides （ TG ） for experimental autoimmune myasthenia gravis（ EAMG） . METHODS：The EAMG rat model was established. The therapeutic efficacy of tripterygium glycosides for EAMG in rats was evaluated by using Lennon scoring and body mass monitoring; the mRNA expression of the BV gene in thymus and in peripheral blood mononuclear cells T-cell receptor（ T-cell receptor, TCR） were detected by quantitative real-time polymerase chain reaction （ RT-PCR ） in complete freund-s adjuvant group,EAMG model group and tripterygium glycosides treatment group. RESULTS： The use of tripterygium glycosides resulted in improvement of the clinical symptoms of myasthenia gravis, reduction of LennonLA score but increase of body mass. The TCR BV gene expression profiles in EAMG rat model presented offset, while the message RNA （ mRNA） expression in tripterygium glycosides group showed reduction （ P 〈0.05 ） . CONCLUSIONS：Treatment of EAMG with tripterygium glycosides effectively alleviated EAMG symptoms, prevent offset of TCR BV gene and reduce the activities of the specificity-activated antigen-reactive T cells.
出处
《中国医院用药评价与分析》
2014年第12期1067-1070,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
黑龙江省教育厅科学技术研究项目(编号:12511585)
